DK170636B1 - 3-Aminomethylderivater af dihydrobenzofuran, dihydrobenzothiophen og indolin og farmaceutisk acceptable syreadditionssalte deraf, en fremgangsmåde til fremstilling deraf og en farmaceutisk komposition heraf - Google Patents

3-Aminomethylderivater af dihydrobenzofuran, dihydrobenzothiophen og indolin og farmaceutisk acceptable syreadditionssalte deraf, en fremgangsmåde til fremstilling deraf og en farmaceutisk komposition heraf Download PDF

Info

Publication number: DK170636B1
Authority: DK; Denmark
Prior art keywords: ppm; formula; compound; dihydro; previously defined
Prior art date: 1987-02-26

Application number

DK091488A

Other languages

Danish (da)

English (en)

Other versions

DK91488D0 (da

DK91488A (da

Inventor

Klaus Peter Boegesoe

Jens Kristian Perregaard

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-02-26

Filing date

1988-02-23

Publication date

1995-11-20

1988-02-23 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

1988-02-23 Publication of DK91488D0 publication Critical patent/DK91488D0/da

1988-08-27 Publication of DK91488A publication Critical patent/DK91488A/da

1995-11-20 Application granted granted Critical

1995-11-20 Publication of DK170636B1 publication Critical patent/DK170636B1/da

Links

238000000034 method Methods 0.000 title claims abstract description 52
238000002360 preparation method Methods 0.000 title claims abstract description 7
150000003839 salts Chemical class 0.000 title claims description 24
239000002253 acid Substances 0.000 title claims description 17
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
HBEDSQVIWPRPAY-UHFFFAOYSA-N dihydro-benzofuran Natural products C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 title description 6
YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 title description 3
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 53
-1 1-aminomethyl Chemical class 0.000 claims abstract description 39
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 5
239000003795 chemical substances by application Substances 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
239000012458 free base Substances 0.000 claims description 8
150000001412 amines Chemical class 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
150000002476 indolines Chemical class 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
239000012954 diazonium Substances 0.000 claims description 2
150000001989 diazonium salts Chemical class 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims 1
239000008023 pharmaceutical filler Substances 0.000 claims 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 8
230000003518 presynaptic effect Effects 0.000 abstract description 7
230000001242 postsynaptic effect Effects 0.000 abstract description 6
210000003169 central nervous system Anatomy 0.000 abstract description 5
201000000980 schizophrenia Diseases 0.000 abstract description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
208000035475 disorder Diseases 0.000 abstract description 2
PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 abstract description 2
230000003287 optical effect Effects 0.000 abstract description 2
208000018737 Parkinson disease Diseases 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 46
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 35
239000000243 solution Substances 0.000 description 31
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 30
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
239000000203 mixture Substances 0.000 description 28
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
229910052757 nitrogen Inorganic materials 0.000 description 22
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 21
229960003638 dopamine Drugs 0.000 description 21
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
239000012074 organic phase Substances 0.000 description 18
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
238000010992 reflux Methods 0.000 description 14
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
238000005481 NMR spectroscopy Methods 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
238000003756 stirring Methods 0.000 description 10
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
241000700159 Rattus Species 0.000 description 9
235000011114 ammonium hydroxide Nutrition 0.000 description 9
229910052943 magnesium sulfate Inorganic materials 0.000 description 9
235000019341 magnesium sulphate Nutrition 0.000 description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
239000002904 solvent Substances 0.000 description 8
102000007527 Autoreceptors Human genes 0.000 description 7
108010071131 Autoreceptors Proteins 0.000 description 7
238000001816 cooling Methods 0.000 description 7
238000000354 decomposition reaction Methods 0.000 description 7
229910052739 hydrogen Inorganic materials 0.000 description 7
239000001257 hydrogen Substances 0.000 description 7
239000012280 lithium aluminium hydride Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 6
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000003826 tablet Substances 0.000 description 6
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 5
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
239000002585 base Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000000600 sorbitol Substances 0.000 description 5
238000005160 1H NMR spectroscopy Methods 0.000 description 4
208000027089 Parkinsonian disease Diseases 0.000 description 4
206010034010 Parkinsonism Diseases 0.000 description 4
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
230000033001 locomotion Effects 0.000 description 4
229940098779 methanesulfonic acid Drugs 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
229960004046 apomorphine Drugs 0.000 description 3
125000003710 aryl alkyl group Chemical group 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
150000002431 hydrogen Chemical group 0.000 description 3
239000012433 hydrogen halide Substances 0.000 description 3
229910000039 hydrogen halide Inorganic materials 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
230000004899 motility Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229920001592 potato starch Polymers 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
238000012360 testing method Methods 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
SJKHKXBRCIBXRD-UHFFFAOYSA-N (5-methoxy-2,3-dihydro-1-benzofuran-2-yl)methanamine Chemical compound COC1=CC=C2OC(CN)CC2=C1 SJKHKXBRCIBXRD-UHFFFAOYSA-N 0.000 description 2
DMLJWJZQSSKQTB-UHFFFAOYSA-N 2-(5-methoxy-2,3-dihydro-1-benzofuran-2-yl)acetic acid Chemical compound COC1=CC=C2OC(CC(O)=O)CC2=C1 DMLJWJZQSSKQTB-UHFFFAOYSA-N 0.000 description 2
NLTUSAXDCOBNEE-UHFFFAOYSA-N 2-[(dipropylamino)methyl]-2,3-dihydro-1-benzofuran-5-ol Chemical compound OC1=CC=C2OC(CN(CCC)CCC)CC2=C1 NLTUSAXDCOBNEE-UHFFFAOYSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
ARDGCAOTHTUMCC-UHFFFAOYSA-N 3-(diethylaminomethyl)-2,3-dihydro-1h-inden-5-ol Chemical compound C1=C(O)C=C2C(CN(CC)CC)CCC2=C1 ARDGCAOTHTUMCC-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
PJPXDBJMAOLQDZ-UHFFFAOYSA-N 5-nitro-1-benzothiophene-3-carboxylic acid Chemical compound C1=C([N+]([O-])=O)C=C2C(C(=O)O)=CSC2=C1 PJPXDBJMAOLQDZ-UHFFFAOYSA-N 0.000 description 2
NYAXSJZIUOHLMW-UHFFFAOYSA-N 6-methoxy-2,3-dihydro-1h-indene-1-carboxylic acid Chemical compound COC1=CC=C2CCC(C(O)=O)C2=C1 NYAXSJZIUOHLMW-UHFFFAOYSA-N 0.000 description 2
UJGDLLGKMWVCPT-UHFFFAOYSA-N 6-methoxy-2,3-dihydroinden-1-one Chemical compound COC1=CC=C2CCC(=O)C2=C1 UJGDLLGKMWVCPT-UHFFFAOYSA-N 0.000 description 2
KYVUGCRGXCNPJD-UHFFFAOYSA-N 6-methoxy-n-(2-phenylethyl)-n-propyl-2,3-dihydro-1h-indene-1-carboxamide Chemical compound C1CC2=CC=C(OC)C=C2C1C(=O)N(CCC)CCC1=CC=CC=C1 KYVUGCRGXCNPJD-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
206010043118 Tardive Dyskinesia Diseases 0.000 description 2
239000000556 agonist Substances 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000012267 brine Substances 0.000 description 2
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
239000012043 crude product Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
150000002367 halogens Chemical group 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
239000012452 mother liquor Substances 0.000 description 2
FCGZOWIIDGEPKE-UHFFFAOYSA-N n-[(5-methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-1-amine Chemical compound COC1=CC=C2OC(CNCCC)CC2=C1 FCGZOWIIDGEPKE-UHFFFAOYSA-N 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000006408 oxalic acid Nutrition 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
239000002243 precursor Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000000018 receptor agonist Substances 0.000 description 2
229940044601 receptor agonist Drugs 0.000 description 2
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
229960003147 reserpine Drugs 0.000 description 2
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
239000000725 suspension Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
QFFIFSJMSMMZQN-UHFFFAOYSA-N 1-[(dipropylamino)methyl]-6-methoxy-2,3-dihydroinden-1-ol Chemical compound C1=C(OC)C=C2C(CN(CCC)CCC)(O)CCC2=C1 QFFIFSJMSMMZQN-UHFFFAOYSA-N 0.000 description 1
GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
OQURWGJAWSLGQG-UHFFFAOYSA-N 1-isocyanatopropane Chemical compound CCCN=C=O OQURWGJAWSLGQG-UHFFFAOYSA-N 0.000 description 1
ZDZHCHYQNPQSGG-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalene Chemical group C1=CC=C2C(C=3C4=CC=CC=C4C=CC=3)=CC=CC2=C1 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 1
QBHALBZXAXQBOY-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-ylmethanamine Chemical class C1=CC=C2C(CN)CCC2=C1 QBHALBZXAXQBOY-UHFFFAOYSA-N 0.000 description 1
JATUDCGOMMSRIP-UHFFFAOYSA-N 2-[[2-phenylethyl(propyl)amino]methyl]-2,3-dihydro-1-benzofuran-5-ol Chemical compound C1C2=CC(O)=CC=C2OC1CN(CCC)CCC1=CC=CC=C1 JATUDCGOMMSRIP-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
KHQVTWFRYJFECV-UHFFFAOYSA-N 3-[(dibutylamino)methyl]-2,3-dihydro-1h-inden-5-ol Chemical compound C1=C(O)C=C2C(CN(CCCC)CCCC)CCC2=C1 KHQVTWFRYJFECV-UHFFFAOYSA-N 0.000 description 1
FZOWJKOGLXLOAK-UHFFFAOYSA-N 3-[(dipropylamino)methyl]-2,3-dihydro-1-benzofuran-5-ol Chemical compound C1=C(O)C=C2C(CN(CCC)CCC)COC2=C1 FZOWJKOGLXLOAK-UHFFFAOYSA-N 0.000 description 1
102100031765 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Human genes 0.000 description 1
ALYNCZNDIQEVRV-UHFFFAOYSA-M 4-aminobenzoate Chemical compound NC1=CC=C(C([O-])=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-M 0.000 description 1
RYVFIFXBZYRFKT-UHFFFAOYSA-N 5-amino-n,n-dipropyl-1-benzothiophene-3-carboxamide Chemical compound C1=C(N)C=C2C(C(=O)N(CCC)CCC)=CSC2=C1 RYVFIFXBZYRFKT-UHFFFAOYSA-N 0.000 description 1
JJVRJLMUWQUDQR-UHFFFAOYSA-N 5-amino-n,n-dipropyl-2,3-dihydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(N)C=C2C(C(=O)N(CCC)CCC)CSC2=C1 JJVRJLMUWQUDQR-UHFFFAOYSA-N 0.000 description 1
DSCPXPBXNGOBAZ-UHFFFAOYSA-N 5-nitro-1-benzofuran-3-carboxylic acid Chemical compound C1=C([N+]([O-])=O)C=C2C(C(=O)O)=COC2=C1 DSCPXPBXNGOBAZ-UHFFFAOYSA-N 0.000 description 1
RYQYUQNNKYFDEE-UHFFFAOYSA-N 5-nitro-n,n-dipropyl-1-benzothiophene-3-carboxamide Chemical compound C1=C([N+]([O-])=O)C=C2C(C(=O)N(CCC)CCC)=CSC2=C1 RYQYUQNNKYFDEE-UHFFFAOYSA-N 0.000 description 1
CZXBVBATQPHSSL-UHFFFAOYSA-N 7-methoxy-2,3-dihydroinden-1-one Chemical compound COC1=CC=CC2=C1C(=O)CC2 CZXBVBATQPHSSL-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
235000021357 Behenic acid Nutrition 0.000 description 1
UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
101000866618 Homo sapiens 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
BGOMCOMWEJULDY-UHFFFAOYSA-N [2-[(dipropylamino)methyl]-2,3-dihydro-1-benzofuran-5-yl] n-(4-methylphenyl)carbamate Chemical compound C=1C=C2OC(CN(CCC)CCC)CC2=CC=1OC(=O)NC1=CC=C(C)C=C1 BGOMCOMWEJULDY-UHFFFAOYSA-N 0.000 description 1
OSTZWTAQVTUKPV-UHFFFAOYSA-N [2-[[methyl(propyl)amino]methyl]-2,3-dihydro-1-benzofuran-5-yl] n-(4-propan-2-ylphenyl)carbamate Chemical compound C=1C=C2OC(CN(C)CCC)CC2=CC=1OC(=O)NC1=CC=C(C(C)C)C=C1 OSTZWTAQVTUKPV-UHFFFAOYSA-N 0.000 description 1
ZCOIAUYHWQMDOU-UHFFFAOYSA-N [2-[[methyl(propyl)amino]methyl]-2,3-dihydro-1-benzofuran-5-yl] n-propylcarbamate Chemical compound CCCNC(=O)OC1=CC=C2OC(CN(C)CCC)CC2=C1 ZCOIAUYHWQMDOU-UHFFFAOYSA-N 0.000 description 1
KLRXIZNXHQJHFP-UHFFFAOYSA-N [3-(diethylaminomethyl)-2,3-dihydro-1h-inden-5-yl] n-(4-propan-2-ylphenyl)carbamate Chemical compound C1=C2C(CN(CC)CC)CCC2=CC=C1OC(=O)NC1=CC=C(C(C)C)C=C1 KLRXIZNXHQJHFP-UHFFFAOYSA-N 0.000 description 1
LNNDTZOPWXLZAC-UHFFFAOYSA-N [3-(diethylaminomethyl)-2,3-dihydro-1h-inden-5-yl] n-propylcarbamate Chemical compound CCCNC(=O)OC1=CC=C2CCC(CN(CC)CC)C2=C1 LNNDTZOPWXLZAC-UHFFFAOYSA-N 0.000 description 1
ZAHDWTRBKQJXTE-UHFFFAOYSA-N [3-[(dipropylamino)methyl]-2,3-dihydro-1h-inden-5-yl] 2-chlorobenzoate Chemical compound C1=C2C(CN(CCC)CCC)CCC2=CC=C1OC(=O)C1=CC=CC=C1Cl ZAHDWTRBKQJXTE-UHFFFAOYSA-N 0.000 description 1
CVKFYPGRTHRZAA-UHFFFAOYSA-N [3-[(dipropylamino)methyl]-2,3-dihydro-1h-inden-5-yl] 2-methoxybenzoate Chemical compound C1=C2C(CN(CCC)CCC)CCC2=CC=C1OC(=O)C1=CC=CC=C1OC CVKFYPGRTHRZAA-UHFFFAOYSA-N 0.000 description 1
229940008309 acetone / ethanol Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
101150024767 arnT gene Proteins 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
229940116226 behenic acid Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical group C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
230000000706 effect on dopamine Effects 0.000 description 1
229950005627 embonate Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
238000006197 hydroboration reaction Methods 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
YIAPLDFPUUJILH-UHFFFAOYSA-N indan-1-ol Chemical class C1=CC=C2C(O)CCC2=C1 YIAPLDFPUUJILH-UHFFFAOYSA-N 0.000 description 1
150000002468 indanes Chemical class 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000155 melt Substances 0.000 description 1
IPZOYWBSELDKGD-UHFFFAOYSA-N methanamine;oxalic acid Chemical compound NC.OC(=O)C(O)=O IPZOYWBSELDKGD-UHFFFAOYSA-N 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
QBMOQPXTXVMMJW-UHFFFAOYSA-N methyl 2-(5-methoxy-1-benzofuran-2-yl)acetate Chemical compound COC1=CC=C2OC(CC(=O)OC)=CC2=C1 QBMOQPXTXVMMJW-UHFFFAOYSA-N 0.000 description 1
WDMQCHWPINFRSL-UHFFFAOYSA-N methyl 2-(5-methoxy-2,3-dihydro-1-benzofuran-2-yl)acetate Chemical compound COC1=CC=C2OC(CC(=O)OC)CC2=C1 WDMQCHWPINFRSL-UHFFFAOYSA-N 0.000 description 1
229940043265 methyl isobutyl ketone Drugs 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
IIIRPZWDICEMGU-UHFFFAOYSA-N n-(2-phenylethyl)propan-1-amine Chemical compound CCCNCCC1=CC=CC=C1 IIIRPZWDICEMGU-UHFFFAOYSA-N 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
NHQWZVBREOYBFY-UHFFFAOYSA-N n-[(5-methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl]-n-methylpropan-1-amine Chemical compound COC1=CC=C2OC(CN(C)CCC)CC2=C1 NHQWZVBREOYBFY-UHFFFAOYSA-N 0.000 description 1
KXIBPIYNKXIUEB-UHFFFAOYSA-N n-[(5-methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl]-n-propylpropan-1-amine Chemical compound COC1=CC=C2OC(CN(CCC)CCC)CC2=C1 KXIBPIYNKXIUEB-UHFFFAOYSA-N 0.000 description 1
AQXDYIDJWQXWBQ-UHFFFAOYSA-N n-[(5-methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl]propanamide Chemical compound COC1=CC=C2OC(CNC(=O)CC)CC2=C1 AQXDYIDJWQXWBQ-UHFFFAOYSA-N 0.000 description 1
CBSKSVYAXRZDJC-UHFFFAOYSA-N n-[(6-methoxy-2,3-dihydro-1h-inden-1-yl)methyl]-n-propylpropan-1-amine Chemical compound C1=C(OC)C=C2C(CN(CCC)CCC)CCC2=C1 CBSKSVYAXRZDJC-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
229960005235 piperonyl butoxide Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000004460 silage Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Furan Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DK091488A 1987-02-26 1988-02-23 3-Aminomethylderivater af dihydrobenzofuran, dihydrobenzothiophen og indolin og farmaceutisk acceptable syreadditionssalte deraf, en fremgangsmåde til fremstilling deraf og en farmaceutisk komposition heraf DK170636B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8704572		1987-02-26
GB878704572A GB8704572D0 (en)	1987-02-26	1987-02-26	Organic compounds

Publications (3)

Publication Number	Publication Date
DK91488D0 DK91488D0 (da)	1988-02-23
DK91488A DK91488A (da)	1988-08-27
DK170636B1 true DK170636B1 (da)	1995-11-20

Family

ID=10613009

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK091488A DK170636B1 (da)	1987-02-26	1988-02-23	3-Aminomethylderivater af dihydrobenzofuran, dihydrobenzothiophen og indolin og farmaceutisk acceptable syreadditionssalte deraf, en fremgangsmåde til fremstilling deraf og en farmaceutisk komposition heraf

Country Status (18)

Country	Link
US (2)	US4847254A (es)
EP (1)	EP0281261B1 (es)
JP (1)	JP2677588B2 (es)
AT (1)	ATE75723T1 (es)
AU (1)	AU608293B2 (es)
CA (1)	CA1338934C (es)
DE (1)	DE3870666D1 (es)
DK (1)	DK170636B1 (es)
ES (1)	ES2037208T3 (es)
FI (1)	FI97380C (es)
GB (1)	GB8704572D0 (es)
GR (1)	GR3004984T3 (es)
IE (1)	IE61257B1 (es)
IL (1)	IL85342A (es)
NO (1)	NO169119C (es)
NZ (1)	NZ223440A (es)
PT (1)	PT86836B (es)
ZA (1)	ZA881217B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE68909253T2 (de) *	1988-01-15	1994-02-24	Abbott Lab	1-Aminomethyl-1,2,3,4-tetrahydronaphthaline und -indane.
JP2931986B2 (ja) *	1989-02-17	1999-08-09	武田薬品工業株式会社	アラルキルアミン誘導体
ATE121740T1 (de) *	1989-03-22	1995-05-15	Ciba Geigy Ag	Neue benzothiopyranylamine.
JPH0318935A (ja) *	1989-06-15	1991-01-28	Hitachi Ltd	データリストに対するアクセスの直列化方式
US5500444A (en) *	1989-11-14	1996-03-19	Hoechst Marion Roussel, Inc.	Cardioprotective tocopherol analogs
IE68675B1 (en) *	1990-11-01	1996-07-10	Takeda Chemical Industries Ltd	Aminocoumaran derivatives their production and use
US5643784A (en) *	1990-12-04	1997-07-01	H, Lundbeck A/S	Indan derivatives
DK36291D0 (da) *	1991-03-01	1991-03-01	Lundbeck & Co As H	Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser
NZ243065A (en) *	1991-06-13	1995-07-26	Lundbeck & Co As H	Piperidine derivatives and pharmaceutical compositions
EP0550292A1 (en) *	1992-01-02	1993-07-07	Merrell Dow Pharmaceuticals Inc.	Tissue protective tocopherol analogs
US5721233A (en) *	1992-04-06	1998-02-24	Merrell Pharmaceuticals Inc.	Derivatives of 2,3-dihydro benzofuranols
US5510373A (en) *	1992-04-06	1996-04-23	Merrell Pharmaceuticals Inc.	Cardioprotective agents
ES2110602T3 (es) *	1992-04-06	1998-02-16	Merrell Pharma Inc	Nuevos derivados de 2,3-dihidro-2,2,4,6,7-pentaalquil-5-benzofuranoles.
US5545660A (en) *	1992-04-07	1996-08-13	Merrell Pharmaceuticals Inc.	Hydrazide derivatives of 3,4-dihydro-2H-1-benzopyrans
DK55192D0 (da) *	1992-04-28	1992-04-28	Lundbeck & Co As H	1-piperazino-1,2-dihydroindenderivater
DK78692D0 (da) *	1992-06-12	1992-06-12	Lundbeck & Co As H	Dimere piperidin- og piperazinderivater
DK148292D0 (da) *	1992-12-09	1992-12-09	Lundbeck & Co As H	Forbindelser
CA2151503C (en) *	1993-01-12	1999-07-20	Yuji Kogami	2,3-dihydrobenzofuran derivatives
US5792791A (en) *	1993-01-12	1998-08-11	Asahi Kasei Kogyo Kabushiki Kaisha	2,3-dihydrobenzofuran derivatives
EP0735821A4 (en) *	1993-12-21	1998-04-01	Lilly Co Eli	METHODS FOR TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH AMYLO DOGEN PEPTIDES
CA2188949A1 (en) *	1994-04-28	1995-11-09	Janusz Jozef Kulagowski	Benzofuran derivatives as d4 receptor antagonists
EP0769496A4 (en) *	1994-07-07	2001-10-17	Asahi Chemical Ind	2,3-DIHYDROBENZOFURAN DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
JPH09124643A (ja) *	1995-08-14	1997-05-13	Bristol Myers Squibb Co	抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
GB9521347D0 (en) *	1995-10-18	1995-12-20	Merck Sharp & Dohme	Therapeutic agents
US5792763A (en) *	1996-10-08	1998-08-11	Eli Lilly And Company	Serotonin 5-HT1F agonists
WO1998055454A2 (en) *	1997-06-05	1998-12-10	Takeda Chemical Industries, Ltd.	Benzofurans and benzothophenes as suppressors of neurodegeneration
US20040067991A1 (en) *	2000-07-06	2004-04-08	Greig Nigel H	Tetrahydrobenzothiazole analogues as neuroprotective agents
TWI320783B (en)	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE623403A (es) *	1962-08-08
US3553093A (en) *	1965-03-19	1971-01-05	Xerox Corp	Color photoelectrophoretic imaging process
US3513239A (en) *	1967-03-15	1970-05-19	Smithkline Corp	Pharmaceutical compositions containing 2-aminoalkyl coumaran derivatives and methods of treating depression therewith
BE786748A (fr) *	1971-07-26	1973-01-26	Basf Ag	1-aminomethyl-indanes-n-substitues
CH601166A5 (es) *	1974-02-14	1978-06-30	Ciba Geigy Ag
JPS535146A (en) *	1976-07-02	1978-01-18	Tanabe Seiyaku Co Ltd	Indane derivatives and their preparation
US4505932A (en) *	1983-05-13	1985-03-19	Abbott Laboratories	Method of producing α2 -adrenergic receptor agonist activity
US4777168A (en) *	1984-10-23	1988-10-11	Rorer Pharmaceutical Corporation	Bicyclic benzo-oxy heterocyclic ethers and thioethers, pharmaceutical compositions and use

1987
- 1987-02-26 GB GB878704572A patent/GB8704572D0/en active Pending
1988
- 1988-02-03 IE IE29788A patent/IE61257B1/en not_active IP Right Cessation
- 1988-02-07 IL IL85342A patent/IL85342A/xx not_active IP Right Cessation
- 1988-02-08 NZ NZ223440A patent/NZ223440A/xx unknown
- 1988-02-09 AT AT88301073T patent/ATE75723T1/de not_active IP Right Cessation
- 1988-02-09 EP EP88301073A patent/EP0281261B1/en not_active Expired - Lifetime
- 1988-02-09 DE DE8888301073T patent/DE3870666D1/de not_active Expired - Lifetime
- 1988-02-09 ES ES198888301073T patent/ES2037208T3/es not_active Expired - Lifetime
- 1988-02-12 US US07/155,354 patent/US4847254A/en not_active Expired - Fee Related
- 1988-02-22 ZA ZA881217A patent/ZA881217B/xx unknown
- 1988-02-23 CA CA000559562A patent/CA1338934C/en not_active Expired - Fee Related
- 1988-02-23 DK DK091488A patent/DK170636B1/da not_active IP Right Cessation
- 1988-02-25 AU AU12167/88A patent/AU608293B2/en not_active Ceased
- 1988-02-25 NO NO880833A patent/NO169119C/no unknown
- 1988-02-25 PT PT86836A patent/PT86836B/pt not_active IP Right Cessation
- 1988-02-26 JP JP63042388A patent/JP2677588B2/ja not_active Expired - Lifetime
- 1988-02-26 FI FI880906A patent/FI97380C/fi not_active IP Right Cessation
1989
- 1989-01-18 US US07/298,630 patent/US4946863A/en not_active Expired - Fee Related
1992
- 1992-06-18 GR GR920401319T patent/GR3004984T3/el unknown

Also Published As

Publication number	Publication date
FI880906A0 (fi)	1988-02-26
JPS63264557A (ja)	1988-11-01
PT86836A (pt)	1988-03-01
PT86836B (pt)	1992-05-29
JP2677588B2 (ja)	1997-11-17
ATE75723T1 (de)	1992-05-15
FI97380B (fi)	1996-08-30
ES2037208T3 (es)	1993-06-16
GR3004984T3 (es)	1993-04-28
US4946863A (en)	1990-08-07
DE3870666D1 (de)	1992-06-11
AU608293B2 (en)	1991-03-28
IE61257B1 (en)	1994-10-19
DK91488D0 (da)	1988-02-23
NO880833L (no)	1988-08-29
US4847254A (en)	1989-07-11
ZA881217B (en)	1989-01-25
NO169119C (no)	1992-05-13
AU1216788A (en)	1988-09-01
NO169119B (no)	1992-02-03
FI97380C (fi)	1996-12-10
FI880906A7 (fi)	1988-08-27
IE880297L (en)	1988-08-26
EP0281261A2 (en)	1988-09-07
EP0281261B1 (en)	1992-05-06
IL85342A (en)	1993-01-14
GB8704572D0 (en)	1987-04-01
DK91488A (da)	1988-08-27
EP0281261A3 (en)	1989-11-23
NZ223440A (en)	1991-02-26
NO880833D0 (no)	1988-02-25
CA1338934C (en)	1997-02-25

Publication	Publication Date	Title
DK170636B1 (da)	1995-11-20	3-Aminomethylderivater af dihydrobenzofuran, dihydrobenzothiophen og indolin og farmaceutisk acceptable syreadditionssalte deraf, en fremgangsmåde til fremstilling deraf og en farmaceutisk komposition heraf
AU637991B2 (en)	1993-06-17	Novel piperazinyl derivatives
US4873262A (en)	1989-10-10	8-Substituted 2-aminotetralins
JPH0419221B2 (es)	1992-03-30
US5288748A (en)	1994-02-22	Centrally acting 6,7,8,9-tetrahydro-3H-benz(e)indole heterocyclics
SK119795A3 (en)	1996-04-03	Indole derivatives as 5-ht1a and/or 5-ht2 ligands
US4139634A (en)	1979-02-13	Indole derivatives and process for preparing the same
US4391821A (en)	1983-07-05	7-Substituted benzopyranes and process for the preparation thereof
JPH03503411A (ja)	1991-08-01	治療上有効なテトラリン誘導体
CA1264741A (en)	1990-01-23	Tetrahydronaphthalene derivatives as dopamine agonists
JPS6135175B2 (es)	1986-08-12
EP1753725B1 (fr)	2013-02-27	Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique
CA1255685A (en)	1989-06-13	Process for preparing 7-¬2-(dialkylamino)ethyl\|-4- hydroxy-1,3-benzimidazol-2-ones
US5272143A (en)	1993-12-21	6-oxoazepinoindole compounds, and pharmaceutical compositions containing them
US5196454A (en)	1993-03-23	Method of treating disorders of the dopaminergic systems using 2,5-diaminotetralines
US4980368A (en)	1990-12-25	Tryptamine compounds, and methods of cerebrovascular treatment therewith
US4705807A (en)	1987-11-10	Amine derivatives
AU2007310769B2 (en)	2011-08-11	Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
JPS6360750B2 (es)	1988-11-25
IE51750B1 (en)	1987-03-18	6,7,8,9-tetrahydro-3h-benz(e)indolamine derivatives,processes for their preparation and intermediates used therein,and pharmaceutical compositions containing the indolamine derivatives
EP0091437A1 (en)	1983-10-19	Therapeutically useful tetralin derivatives iii, processes for preparation and pharmaceutical preparations for such compounds
US4425351A (en)	1984-01-10	Therapeutically useful oxygen derivatives of 3,7a-diazacyclohepta[j,k]fluorenes
CZ284463B6 (cs)	1998-12-16	N-Substituované azabicykloheptanové deriváty
FR2737723A1 (fr)	1997-02-14	Derives de 1-(2-(1h-inden-3-yl)ethyl)-4-(naphtalen-1-yl)- piperazine, leur preparation et leur application en therapeutique

Legal Events

Date	Code	Title	Description
1995-11-20	B1	Patent granted (law 1993)
1999-05-17	PBP	Patent lapsed